DROSPIRENONE AND ESTRADIOL (drospirenone; estradiol) by Novast Labs is characteristics. Approved for moderate to severe vasomotor symptoms due to menopause in a woman with a uterus, moderate to severe vasomotor symptoms associated due to menopause in a woman with a uterus, moderate to severe symptoms of vulvar and 2 more indications. First approved in 2025.
Drug data last refreshed 13h ago
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol (E2) is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of…
Worked on DROSPIRENONE AND ESTRADIOL at Novast Labs? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.